key: cord-0945484-aolrf8hs
authors: Cheruiyot, Isaac; Kipkorir, Vincent; Ngure, Brian; Misiani, Musa; Munguti, Jeremiah; Ogeng’o, Julius
title: Arterial Thrombosis in Coronavirus disease 2019 (COVID-19) Patients: A Rapid Systematic Review
date: 2020-08-28
journal: Ann Vasc Surg
DOI: 10.1016/j.avsg.2020.08.087
sha: c0aed15cbab213fe85b31dd7fc5b27f6758fd220
doc_id: 945484
cord_uid: aolrf8hs

BACKGROUND: Emerging evidence suggests that severe form of COVID-19 is mediated, in part, by a hypercoagulable state characterized by micro- and macrovascular thrombotic angiopathy. Whereas venous thrombotic events in COVID-19 patients has been well described, data on arterial thrombosis (AT) in these patients is still limited. We, therefore, conducted a rapid systematic review of current scientific literature to identify and consolidate evidence of AT in COVID-19 patients. METHODS: A systematic search of literature was conducted between 1(st) November 2019 and 9(th) June 2020 on PubMed and China National Knowledge Infrastructure to identify potentially eligible studies. RESULTS: A total of 27 studies (5 cohort, 5 case series & 17 case reports) describing arterial thrombotic events in 90 COVID-19 patients were included. The pooled incidence of AT in severe/critically ill ICU-admitted COVID-19 patients across the 5 cohort studies was 4.4% (95% CI 2.8-6.4). Most of the patients were male, elderly and had comorbidities. AT was symptomatic in >95% of these patients, and involved multiple arteries in about 18% of patients. The anatomical distribution of arterial thrombotic events was wide, occurring in limb arteries (39%), cerebral arteries (24%), great vessels (aorta, common iliac, common carotid and brachiocephalic trunk) (19%); coronary arteries (9%) and superior mesenteric artery (8%). Mortality rate in these patients is about 20%. CONCLUSION: Arterial thrombosis occurs in approximately 4% of critically-ill COVID-19 patients. It often presents symptomatically, and can affect multiple arteries. Further investigation of the underlying mechanism of AT in COVID-19 would be needed to clarify possible therapeutic targets

Cochrane's Q p value of <0.10 was considered significant. An I 2 of <40% was considered not significant. Additionally, a leave-one-out sensitivity analysis was performed to assess the 144 robustness of the results and to further probe the sources of inter-study heterogeneity. 

Study identification 148 The initial search produced 185 potentially relevant articles. Following the removal of duplicates 149 and primary screening, 85 articles were assessed by full text for eligibility in the meta-analysis.

Of these, 58 were excluded because the primary and secondary outcome of the study did not 151 match that of this review. Thus, a total of 27 articles were included in this systematic review and Table 1 ). 

Five cohort studies (n=537 patients) reported data on the incidence of arterial thrombosis (AT) in 163 severe/critically ill ICU-admitted COVID-19 patients, with the incidence ranging from 2.7%-164 8%. 11,19,24,28,34 The pooled incidence of AT across these five studies was 4.4% (95% CI 2.8-6.4), with no inter-study heterogeneity observed (I 2 =0%, Cochran's Q=3.908, p=0.419) (Figure 2 Findings from this study suggest that the mortality rate in COVID-19 patients with AT could be 245 around 20%, and this is mainly driven by the presence of end-organ injury as evidenced by the 246 various acute ischemic events as recorded in our analysis.

Our study was limited by the small number of included studies, which were mainly case reports 248 and case series. Larger well-designed studies are urgently needed to confirm these findings. 

Statement-on-the-second-meeting-of-the

n (%) Male Andrea et al., 12 Italy Case Report